Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts

Purpose: Patients with luminal breast cancer (LBC) often become endocrine resistant over time. We investigated the molecular changes associated with acquired hormonoresistances in patient-derived xenografts of LBC. Experimental Design: Two LBC xenografts (HBCx22 and HBCx34) were treated with different endocrine treatments (ET) to obtain xenografts with acquired resistances to tamoxifen (TamR) and ovariectomy (OvaR). PI3K pathway activation was analyzed by Western blot analysis and IHC and responses to ET combined to everolimus were investigated in vivo. Gene expression analyses were performed by RT-PCR and Affymetrix arrays. Results: HBCx22 TamR xenograft was cross-resistant to several hormonotherapies, whereas HBCx22 OvaR and HBCx34 TamR exhibited a treatment-specific resistance profile. PI3K pathway was similarly activated in parental and resistant xenografts but the addition of everolimus did not restore the response to tamoxifen in TamR xenografts. In contrast, the combination of fulvestrant and everolimus induced tumor regression in vivo in HBCx34 TamR, where we found a cross-talk between the estrogen receptor (ER) and PI3K pathways. Expression of several ER-controlled genes and ER coregulators was significantly changed in both TamR and OvaR tumors, indicating impaired ER transcriptional activity. Expression changes associated with hormonoresistance were both tumor and treatment specific and were enriched for genes involved in cell growth, cell death, and cell survival. Conclusions: PDX models of LBC with acquired resistance to endocrine therapies show a great diversity of resistance phenotype, associated with specific deregulations of ER-mediated gene transcription. These models offer a tool for developing anticancer therapies and to investigate the dynamics of resistance emerging during pharmacologic interventions. Clin Cancer Res; 20(16); 4314–25. ©2014 AACR.

[1]  Li Ding,et al.  Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. , 2013, Cell reports.

[2]  C. Sotiriou,et al.  Luminal breast cancer: from biology to treatment , 2013, Nature Reviews Clinical Oncology.

[3]  C. Korch,et al.  Transcription Factor Ets1 Cooperates with Estrogen Receptor α to Stimulate Estradiol-Dependent Growth in Breast Cancer Cells and Tumors , 2013, PloS one.

[4]  A. Lánczky,et al.  A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer , 2013, Breast Cancer Research and Treatment.

[5]  R. Moreau,et al.  Gene- and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis. , 2013, Journal of hepatology.

[6]  A. Lánczky,et al.  Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer , 2013, Proceedings of the National Academy of Sciences.

[7]  Carlos Caldas,et al.  Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. , 2013, Cell reports.

[8]  K. Gelmon,et al.  Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. , 2013, Current oncology.

[9]  M. Jouvenot,et al.  Epigenetic regulation of estrogen signaling in breast cancer , 2013, Epigenetics.

[10]  Jenny C. Chang,et al.  Patient-derived breast tumor xenografts facilitating personalized cancer therapy , 2013, Breast Cancer Research.

[11]  V. Theodorou,et al.  GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility , 2013, Genome research.

[12]  F. Kleinclauss,et al.  Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer , 2012, Clinical Medicine Insights. Oncology.

[13]  M. Dowsett,et al.  Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo , 2012, Breast Cancer Research.

[14]  Xiaohong Liu,et al.  Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts , 2012, Molecular Cancer Therapeutics.

[15]  R. Nicholson,et al.  Tamoxifen-Induced Epigenetic Silencing of Oestrogen-Regulated Genes in Anti-Hormone Resistant Breast Cancer , 2012, PloS one.

[16]  A. Vincent-Salomon,et al.  Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts , 2012, Breast Cancer Research and Treatment.

[17]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[18]  J. Carroll,et al.  Pioneer factors in hormone-dependent cancers , 2012, Nature Reviews Cancer.

[19]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.

[20]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[21]  Samuel Leung,et al.  FOXA1 is an independent prognostic marker for ER-positive breast cancer , 2012, Breast Cancer Research and Treatment.

[22]  Anne Vincent-Salomon,et al.  Molecular profiling of patient-derived breast cancer xenografts , 2012, Breast Cancer Research.

[23]  I. Ellis,et al.  Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.

[24]  Mathieu Lupien,et al.  PBX1 Genomic Pioneer Function Drives ERα Signaling Underlying Progression in Breast Cancer , 2011, PLoS genetics.

[25]  S. O'toole,et al.  Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer , 2011, Oncogene.

[26]  G. Mills,et al.  High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. , 2011, Cancer discovery.

[27]  Hayley E. Francies,et al.  Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1 , 2011, Breast Cancer Research.

[28]  M. Ellis,et al.  Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer , 2011, Breast Cancer Research.

[29]  Rachel Schiff,et al.  Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.

[30]  M. Lichinitser,et al.  Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Pieter Wesseling,et al.  Receptor conversion in distant breast cancer metastases , 2010, Breast Cancer Research.

[32]  W. Miller,et al.  Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole , 2010, Breast Cancer Research.

[33]  Robert L. Sutherland,et al.  Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.

[34]  Emmanuel Barillot,et al.  Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells , 2008, Breast Cancer Research.

[35]  Jiang Shou,et al.  Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. , 2008, Cancer research.

[36]  Margaret Gardiner-Garden,et al.  Identification of Functional Networks of Estrogen- and c-Myc-Responsive Genes and Their Relationship to Response to Tamoxifen Therapy in Breast Cancer , 2008, PloS one.

[37]  Xin Wang,et al.  Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. , 2008, Cancer research.

[38]  M. Beeram,et al.  Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  A. Vincent-Salomon,et al.  A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays , 2007, Clinical Cancer Research.

[40]  Urs Eppenberger,et al.  Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer , 2007, BMC Cancer.

[41]  S. Vacher,et al.  Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. , 2006, Endocrine-related cancer.

[42]  A. Howell.  Fulvestrant ('Faslodex'): current and future role in breast cancer management. , 2006, Critical reviews in oncology/hematology.

[43]  Hans-Dieter Pohlenz,et al.  Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. , 2005, Molecular cancer therapeutics.

[44]  Manuel Hidalgo,et al.  Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity , 2004, Clinical Cancer Research.

[45]  Mitch Dowsett,et al.  Mechanisms of tamoxifen resistance. , 2004, Endocrine-related cancer.

[46]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[47]  Jiang Shou,et al.  Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.

[48]  L. Seymour,et al.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  I. Bièche,et al.  Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. , 2001, Cancer research.

[50]  P. Lønning.  Clinico-pharmacological aspects of different hormone treatments. , 2000, European journal of cancer.

[51]  M. Salgaller.  American Association for Cancer Research , 2000, Expert opinion on investigational drugs.